Stauffer, S.; Roth, J.S.; Hernandez, E.R.; Kowalczyk, J.T.; Sealover, N.E.; Hebron, K.E.; James, A.; Isanogle, K.A.; Riffle, L.A.; Ileva, L.;
et al. Preclinical Therapeutic Efficacy of RAF/MEK/ERK and IGF1R/AKT/mTOR Inhibition in Neuroblastoma. Cancers 2024, 16, 2320.
https://doi.org/10.3390/cancers16132320
AMA Style
Stauffer S, Roth JS, Hernandez ER, Kowalczyk JT, Sealover NE, Hebron KE, James A, Isanogle KA, Riffle LA, Ileva L,
et al. Preclinical Therapeutic Efficacy of RAF/MEK/ERK and IGF1R/AKT/mTOR Inhibition in Neuroblastoma. Cancers. 2024; 16(13):2320.
https://doi.org/10.3390/cancers16132320
Chicago/Turabian Style
Stauffer, Stacey, Jacob S. Roth, Edjay R. Hernandez, Joshua T. Kowalczyk, Nancy E. Sealover, Katie E. Hebron, Amy James, Kristine A. Isanogle, Lisa A. Riffle, Lilia Ileva,
and et al. 2024. "Preclinical Therapeutic Efficacy of RAF/MEK/ERK and IGF1R/AKT/mTOR Inhibition in Neuroblastoma" Cancers 16, no. 13: 2320.
https://doi.org/10.3390/cancers16132320
APA Style
Stauffer, S., Roth, J. S., Hernandez, E. R., Kowalczyk, J. T., Sealover, N. E., Hebron, K. E., James, A., Isanogle, K. A., Riffle, L. A., Ileva, L., Luo, X., Chen, J. -Q., Kedei, N., Kortum, R. L., Lei, H., Shern, J. F., Kalen, J. D., Edmondson, E. F., Hall, M. D.,
... Yohe, M. E.
(2024). Preclinical Therapeutic Efficacy of RAF/MEK/ERK and IGF1R/AKT/mTOR Inhibition in Neuroblastoma. Cancers, 16(13), 2320.
https://doi.org/10.3390/cancers16132320